Advagene Biopharma (TPEX:6709) - Share price, News & Analysis

6709 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

6709 Stock Overview

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan.

Risk Analysis

Makes less than USD$1m in revenue (NT$0)

Volatile share price over the past 3 months

Does not have a meaningful market cap (NT$2B)

Advagene Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Advagene Biopharma
Historical stock prices
Current Share Price	NT$38.70
52 Week High	NT$74.70
52 Week Low	NT$38.00
Beta	0.89
1 Month Change	-17.83%
3 Month Change	-17.04%
1 Year Change	-40.74%
3 Year Change	88.78%
5 Year Change	n/a
Change since IPO	47.15%

Recent News & Updates

Mar 24

Advagene Biopharma (GTSM:6709) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Advagene Biopharma...

Dec 10

Here's Why We're Not At All Concerned With Advagene Biopharma's (GTSM:6709) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

	6709	TW Pharmaceuticals	TW Market
7D	-1.5%	-2.0%	-0.8%
1Y	-40.7%	3.2%	4.2%

Return vs Industry: 6709 underperformed the TW Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: 6709 underperformed the TW Market which returned 4.2% over the past year.

Price Volatility

Is 6709's price volatile compared to industry and market?
6709 volatility
6709 Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.3%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6709 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 6709's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

Founded	Employees	CEO	Website
n/a	11	Chen Bryon	https://www.advagene.com.tw

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, other vaccines, etc. The company was founded in 1995 and is based in Taipei, Taiwan.

Advagene Biopharma Fundamentals Summary

How do Advagene Biopharma's earnings and revenue compare to its market cap?
6709 fundamental statistics
Market Cap	NT$1.91b
Earnings (TTM)	-NT$92.69m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-20.6x

P/E Ratio

Is 6709 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
6709 income statement (TTM)
Revenue	NT$0
Cost of Revenue	NT$0
Gross Profit	NT$0
Other Expenses	NT$92.69m
Earnings	-NT$92.69m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.88
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 6709 perform over the long term?

See historical performance and comparison

Valuation

Is Advagene Biopharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

7.64x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6709's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6709's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 6709 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6709 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6709's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6709 is overvalued based on its PB Ratio (7.6x) compared to the TW Pharmaceuticals industry average (2x).

Future Growth

How is Advagene Biopharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

51.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advagene Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Advagene Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

12.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6709 is currently unprofitable.

Growing Profit Margin: 6709 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 6709 is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.

Accelerating Growth: Unable to compare 6709's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6709 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).

Return on Equity

High ROE: 6709 has a negative Return on Equity (-37.14%), as it is currently unprofitable.

Financial Health

How is Advagene Biopharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6709's short term assets (NT$244.0M) exceed its short term liabilities (NT$8.3M).

Long Term Liabilities: 6709's short term assets (NT$244.0M) exceed its long term liabilities (NT$2.6M).

Debt to Equity History and Analysis

Debt Level: 6709 is debt free.

Reducing Debt: 6709 has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6709 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6709 has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 9.7% each year.

Dividend

What is Advagene Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6709's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6709's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6709's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6709's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6709 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure

CEO

Chen Bryon

no data

Tenure

Mr. Bryon Chen serves as Chairman and CEO of Advagene biopharma Co.,Ltd.

Board Members

Experienced Board: 6709's board of directors are considered experienced (3.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/17 00:00
End of Day Share Price	2022/05/17 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31